By Peter G. Traber, M.D. on December 7, 2015 In June 2015 Galectin Therapeutics initiated a clinical trial to determine if our investigational drug GR-MD-02 can successfully treat patients with...
Read More
By Peter G. Traber, M.D. on October 21, 2015 Bristol-Myers Squibb ($BMS) recently paid $150 million for the exclusive right to acquire Promedior, a clinical-stage biotechnology company in the midst...
Read More
By Peter G. Traber, M.D. on October 15, 2015 When thinking about the development of a drug, one naturally tends to think of performing animal and human studies to demonstrate...
Read More
Written by Peter G. Traber, M.D. on October 8, 2015 On September 14, 2015, Raptor Pharmaceutical Corp. (NASDAQ: RPTP) announced top-line results of its Phase 2b trial evaluating RP103 in...
Read More
Written by Peter G. Traber, M.D. on September 9, 2015 An important question in drug development, and the subject of U.S. Food and Drug Administration (FDA) regulations, is whether a...
Read More
Written by Peter G. Traber, M.D. on September 2, 2015 In late June 2015, Galectin Therapeutics initiated a Phase 2 clinical trial (the NASH-CX trial) to evaluate the ability of...
Read More Successful Phase 1 Clinical Trial Supports Phase 2 Clinical Development Program
1 Comments , in Article
Written by Peter G. Traber, M.D. on August 24, 2015 Galectin Therapeutics completed and reported on a successful Phase 1 clinical trial in NASH patients with advanced fibrosis. In a...
Read More
Written by Peter G. Traber, M.D. on August 17, 2015 Galectin Therapeutics is developing a drug called GR-MD-02 which binds to and inhibits the galectin-3 protein which is important in...
Read More
Written by Peter G. Traber, M.D. on July 31, 2015 During the normal course of conducting business in a public company like Galectin Therapeutics, as the CEO and Chief Medical...
Read More